Vistagen Therapeutics Stock Performance
| VTGN Stock | USD 2.48 0.03 1.20% |
The entity has a beta of 0.5, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, VistaGen Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding VistaGen Therapeutics is expected to be smaller as well. At this point, VistaGen Therapeutics has a negative expected return of -0.35%. Please make sure to validate VistaGen Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if VistaGen Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days VistaGen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (1.20) | Five Day Return (4.62) | Year To Date Return (51.84) | Ten Year Return (99.08) | All Time Return (99.83) |
Last Split Factor 1:30 | Last Split Date 2023-06-07 |
1 | Acquisition by Fitzpatrick Margaret M of 12500 shares of VistaGen Therapeutics at 4.85 subject to Rule 16b-3 | 09/18/2024 |
2 | Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder | 09/23/2024 |
3 | Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day | 10/09/2024 |
4 | Acquisition by Snodgrass H. Ralph of 1111 shares of VistaGen Therapeutics subject to Rule 16b-3 | 10/30/2024 |
5 | Vistagen to Present at the 2024 Neuroscience Education Institute Congress | 11/05/2024 |
6 | Vistagen Therapeutics Inc Q2 2025 Earnings Report Preview What to Expect | 11/06/2024 |
7 | VistaGen Therapeutics GAAP EPS of -0.42 misses by 0.03, revenue of 0.18M beats by 0.15M | 11/07/2024 |
8 | Vistagen Therapeutics Inc Q2 2025 Earnings Call Highlights Navigating Challenges with a ... | 11/08/2024 |
9 | Vistagen to Present at the Stifel 2024 Healthcare Conference | 11/14/2024 |
10 | Anxiety drug trials keep Stifel optimistic on VistaGen stocks upside potential | 11/21/2024 |
11 | VTGN Stock Touches 52-Week Low at 2.47 Amid Market Challenges By Investing.com - Investing.com South Africa | 12/10/2024 |
| Begin Period Cash Flow | 16.6 M |
VistaGen |
VistaGen Therapeutics Relative Risk vs. Return Landscape
If you would invest 315.00 in VistaGen Therapeutics on September 14, 2024 and sell it today you would lose (67.00) from holding VistaGen Therapeutics or give up 21.27% of portfolio value over 90 days. VistaGen Therapeutics is currently does not generate positive expected returns and assumes 2.5629% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than VistaGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
VistaGen Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VistaGen Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as VistaGen Therapeutics, and traders can use it to determine the average amount a VistaGen Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1352
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VTGN |
Estimated Market Risk
| 2.56 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average VistaGen Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VistaGen Therapeutics by adding VistaGen Therapeutics to a well-diversified portfolio.
VistaGen Therapeutics Fundamentals Growth
VistaGen Stock prices reflect investors' perceptions of the future prospects and financial health of VistaGen Therapeutics, and VistaGen Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VistaGen Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (77.74) % | ||||
| Current Valuation | (25.9 M) | ||||
| Shares Outstanding | 27.84 M | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 79.75 X | ||||
| Revenue | 1.06 M | ||||
| Gross Profit | (227.3 K) | ||||
| EBITDA | (32.45 M) | ||||
| Net Income | (29.36 M) | ||||
| Cash And Equivalents | 51.99 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 2.12 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (25.81 M) | ||||
| Earnings Per Share | (0.74) X | ||||
| Market Capitalization | 69.89 M | ||||
| Total Asset | 123.65 M | ||||
| Retained Earnings | (356.21 M) | ||||
| Working Capital | 115.55 M | ||||
| Current Asset | 6.91 M | ||||
| Current Liabilities | 1.8 M | ||||
About VistaGen Therapeutics Performance
By examining VistaGen Therapeutics' fundamental ratios, stakeholders can obtain critical insights into VistaGen Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that VistaGen Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (605.67) | (575.38) | |
| Return On Tangible Assets | (0.24) | (4.08) | |
| Return On Capital Employed | (0.28) | 8.95 | |
| Return On Assets | (0.24) | (4.08) | |
| Return On Equity | (0.26) | 8.98 |
Things to note about VistaGen Therapeutics performance evaluation
Checking the ongoing alerts about VistaGen Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for VistaGen Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VistaGen Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 1.06 M. Net Loss for the year was (29.36 M) with loss before overhead, payroll, taxes, and interest of (227.3 K). | |
| VistaGen Therapeutics currently holds about 51.99 M in cash with (25.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| VistaGen Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: VTGN Stock Touches 52-Week Low at 2.47 Amid Market Challenges By Investing.com - Investing.com South Africa |
- Analyzing VistaGen Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VistaGen Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining VistaGen Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VistaGen Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VistaGen Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VistaGen Therapeutics' stock. These opinions can provide insight into VistaGen Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.